Scleroderma Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Boehringer Ingelheim GmbH, Celgene Crp, Johnson & Johnson Services, Inc., Prometic Life Sci

.
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Scleroderma pipeline constitutes 45+ key companies continuously working towards developing 50+ Scleroderma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Scleroderma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Scleroderma Market.

The Scleroderma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Scleroderma Pipeline Report: https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Scleroderma treatment therapies with a considerable amount of success over the years.
• Scleroderma companies working in the treatment market are Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Scleroderma treatment
• Emerging Scleroderma therapies in the different phases of clinical trials are- RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others are expected to have a significant impact on the Scleroderma market in the coming years.
• In December 2023, The Scleroderma Research Foundation (SRF), the largest non-profit supporter of scleroderma research in the nation, has announced that the FDA has granted clearance for its Investigational New Drug application (IND) to launch the CONQUEST clinical trial platform and commence patient enrollment. Sanofi and Boehringer Ingelheim are the initial pharmaceutical partners to pledge their support to this protocol, aimed at expediting the development of new scleroderma treatments. The first two nominated investigational drugs will undergo evaluation for safety and efficacy in scleroderma patients affected by interstitial lung disease (SSc-ILD). Amlitelimab, a non-depleting monoclonal antibody targeting OX40-Ligand, represents the Sanofi agent, while BI-1015550, an oral PDE-4B inhibitor, is the agent from Boehringer Ingelheim. Both investigational agents have exhibited promising preliminary efficacy in previous clinical trials for non-scleroderma indications in altering disease processes.
• In November 2023, Certa Therapeutics intends to initiate a pivotal trial with FT011 in late 2024, building on encouraging Phase II trial results in scleroderma. Certa aims to engage in discussions regarding the pivotal trial design and related development strategies with the US Food and Drug Administration (FDA) in early 2024. Additionally, the company plans to seek supplementary scientific guidance from the European Medicines Agency (EMA) in mid-2024.
• In October 2023, The US Food and Drug Administration (FDA) has awarded orphan drug designation to Certa Therapeutics' FT011 for the treatment of scleroderma. With this status, the company becomes eligible for tax credits for eligible clinical trials, waivers for specific FDA fees, and a potential seven-year market exclusivity if FT011 receives approval. Certa recently completed a Phase II trial (NCT04647890) evaluating FT011, an orally administered anti-fibrotic agent, in scleroderma patients.
• In November 2022, Horizon Pharmaceuticals initiated a multicenter, open-label extension trial to evaluatethe efficacy, safety and tolerability of HZN-825 in patients with diffuse cutaneous systemic sclerosis. This is an open-label,repeat-dose, multicenter extension trial of HZNP-HZN-825-301.

Scleroderma Overview
Scleroderma is a rare autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. It is caused by an overproduction of collagen, which leads to fibrosis or scarring in various parts of the body. Scleroderma can affect the skin, blood vessels, muscles, and internal organs such as the lungs, heart, kidneys, and digestive system.

Get a Free Sample PDF Report to know more about Scleroderma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Scleroderma Drugs Under Different Phases of Clinical Development Include:
• RO7303509: Genentech
• AM 1476: AnaMar AB
• MK-2225: Acceleron Pharma
• BI 685509: Boehringer Ingelheim
• Brentuximab: Vedotin Seagen
• HZN-825: Horizon Pharmaceuticals
• MT-0551: Mitsubishi Tanabe PharmaCorporation

Scleroderma Route of Administration
Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Scleroderma Molecule Type
Scleroderma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scleroderma Pipeline Therapeutics Assessment
• Scleroderma Assessment by Product Type
• Scleroderma By Stage and Product Type
• Scleroderma Assessment by Route of Administration
• Scleroderma By Stage and Route of Administration
• Scleroderma Assessment by Molecule Type
• Scleroderma by Stage and Molecule Type

DelveInsight's Scleroderma Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Scleroderma product details are provided in the report. Download the Scleroderma pipeline report to learn more about the emerging Scleroderma therapies at:
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Scleroderma Therapeutics Market include:
Key companies developing therapies for Scleroderma are - Boehringer Ingelheim International GmbH, Celgene Corporation, Johnson & Johnson Services, Inc., Prometic Life Sciences Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals, Cytori Therapeutics Inc., Bayer AG, F. Hoffman La Roche Ltd, arGentis Pharmaceuticals LLC, GlaxoSmithKline PLC (GSK), Novartis AG, and others.

Scleroderma Pipeline Analysis:
The Scleroderma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.
• Scleroderma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Scleroderma drugs and therapies-
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scleroderma Pipeline Market Drivers
• Pharmaceutical and Biotechnology Industries striving on the development of new therapy, increased Awareness among people related to the disease are some of the important factors that are fueling the Scleroderma Market.

Scleroderma Pipeline Market Barriers
• However, higher healthcare cost, adverse effects associated with the drugs and other factors are creating obstacles in the Scleroderma Market growth.

Scope of Scleroderma Pipeline Drug Insight
• Coverage: Global
• Key Scleroderma Companies: Genentech, AnaMar AB, Acceleron Pharma, Boehringer Ingelheim, Vedotin Seagen, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and others
• Key Scleroderma Therapies: RO7303509, AM 1476, MK-2225, BI 685509, Brentuximab, HZN-825, MT-0551, and others
• Scleroderma Therapeutic Assessment: Scleroderma current marketed and Scleroderma emerging therapies
• Scleroderma Market Dynamics: Scleroderma market drivers and Scleroderma market barriers

Request for Sample PDF Report for Scleroderma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Scleroderma Report Introduction
2. Scleroderma Executive Summary
3. Scleroderma Overview
4. Scleroderma- Analytical Perspective In-depth Commercial Assessment
5. Scleroderma Pipeline Therapeutics
6. Scleroderma Late Stage Products (Phase II/III)
7. Scleroderma Mid Stage Products (Phase II)
8. Scleroderma Early Stage Products (Phase I)
9. Scleroderma Preclinical Stage Products
10. Scleroderma Therapeutics Assessment
11. Scleroderma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Scleroderma Key Companies
14. Scleroderma Key Products
15. Scleroderma Unmet Needs
16 . Scleroderma Market Drivers and Barriers
17. Scleroderma Future Perspectives and Conclusion
18. Scleroderma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Scleroderma Market
https://www.delveinsight.com/report-store/scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Scleroderma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.